MS4A1 and non-Hodgkin lymphoma: Recent advances in the treatment of NHL, such as the combination of rituximab, an anti-CD20 monoclonal antibody, with multiagent chemotherapy regimens or the use of brentuximab, an anti-CD30 antibody-drug conjugate, have improved EFS and OS rates in pediatric and adolescent patients with primary NHL [5].